Caravella Biopharma
- Biotech or pharma, therapeutic R&D
Caravella Biopharma SA (Caravella) is a Swiss biotech who has developed a high purity, high activity recombinant human Alpha-1 antitrypsin – named CAR01– that can be formulated as a dry powder for inhalation or for IV administration.
CAR01 is differentiated from plasma derived AAT by its high specific activity, high purity, flexibility in formulations and the fact that it can be produced in unlimited quantities as it does not rely on donor plasma as a raw material.
Caravella is seeking to partner CAR01 for clinical development.
Address
MontheySwitzerland
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}